SCHEMBL5714080

SCHEMBL5714080

Cc1ccc(N2CCN(C(=O)Oc3ccc(Cc4cc(C)ccn4)cc3)CC2)nc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PANK3 Q9H999 3/20 0.48
HRH3 Q9Y5N1 2/20 0.46
SMN1; SMN2 Q16637 3/20 0.42
HPGD P15428 1/20 0.42
GPR119 Q8TDV5 2/20 0.42
ME2 P23368 2/20 0.41
ME1 P48163 2/20 0.41
ME3 Q16798 2/20 0.41
SMO Q99835 1/20 0.41
PPARG P37231 1/20 0.41
PPARA Q07869 1/20 0.41
KDM4E B2RXH2 2/20 0.41
WNT3A P56704 1/20 0.41
KEAP1 Q14145 1/20 0.40
NFE2L2 Q16236 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
DRD2 P14416 1/20 0.39
DRD1 P21728 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5715211 0.92 PANK3 (0.48) PANK3SMN1; SMN2HPGDGPR119ME2
SCHEMBL5714885 0.92 PANK3 (0.46) PANK3HRH3SMN1; SMN2HPGDGPR119
SCHEMBL5714994 0.91 PANK3 (0.46) PANK3HRH3SMN1; SMN2HPGDGPR119
SCHEMBL5714845 0.91 HRH3 (0.46) PANK3HRH3SMN1; SMN2HPGDGPR119
SCHEMBL5715642 0.91 PANK3 (0.46) PANK3HRH3SMN1; SMN2HPGDGPR119
SCHEMBL5715323 0.89 SMN1; SMN2 (0.59) HRH3SMN1; SMN2HPGDKDM4ECYP1A2
SCHEMBL5714218 0.89 PANK3 (0.53) PANK3HRH3SMN1; SMN2HPGDGPR119
SCHEMBL5714769 0.88 HSD17B10 (0.53) SMN1; SMN2HPGDSMOKDM4ECYP1A2
SCHEMBL5715207 0.88 KDM4E (0.50) PANK3HRH3SMN1; SMN2HPGDSMO
SCHEMBL5715636 0.85 SMO (0.42) PANK3SMN1; SMN2HPGDSMOKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160819-A1 Substitued piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
CN-1798735-A 1-aryl-4- (aryloxycarbonyl) -piperazine derivatives as inhibitors of hormone sensitive lipase NOVO NORDISK AS (DK) 2006-07-05 CN claimed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
CN-1798735-A 1-aryl-4- (aryloxycarbonyl) -piperazine derivatives as inhibitors of hormone sensitive lipase NOVO NORDISK AS (DK) 2006-07-05 CN disclosed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160819-A1 Substitued piperazine carbamates LIPE, PNLIP, LIPC PANK3 1247/4885HRH3 1098/4885SMN1; SMN2 2732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.